Globus Medical (NYSE:GMED) Upgraded by Zacks Research to Strong-Buy Rating

Posted by Francis Steltz on Aug 12th, 2026

Zacks Research upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a strong-buy rating in a report published on Monday morning,Zacks.com reports.

A number of other equities analysts have also recently weighed in on GMED. Royal Bank Of Canada lowered their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group assumed coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. BMO Capital Markets began coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Finally, Wells Fargo & Company lowered their target price on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $101.77.

Get Our Latest Research Report on GMED

Globus Medical Stock Performance

GMED opened at $85.13 on Monday. Globus Medical has a one year low of $54.15 and a one year high of $101.40. The stock has a market capitalization of $11.56 billion, a PE ratio of 21.77, a P/E/G ratio of 1.39 and a beta of 0.95. The business’s 50 day moving average price is $79.59 and its 200 day moving average price is $85.06.

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities research analysts forecast that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. increased its stake in Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after buying an additional 3,595,339 shares during the period. Bank of Montreal Can lifted its holdings in Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. boosted its position in Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after buying an additional 1,908,795 shares during the period. Fuller & Thaler Asset Management Inc. purchased a new position in Globus Medical in the 4th quarter valued at approximately $90,411,000. Finally, Norges Bank acquired a new position in shares of Globus Medical in the fourth quarter worth $89,922,000. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

(Get Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.